Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.10 USD
Change Today -0.19 / -2.61%
Volume 130.0K
XNPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:04 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - xenoport inc (XNPT)

Name (Connections)Board RelationshipsTitleKey Developments
John Freund M.D. 92 RelationshipsLead Director, Chairman of Nominating & Corporate Governance Committee and Member of Audit Committee 
Jeryl Hilleman M.B.A 7 RelationshipsIndependent Director and Chairman of Audit Committee 
Catherine Friedman 30 RelationshipsDirector, Member of Nominating & Corporate Governance Committee and Member of Audit Committee 

Compensation Committee* - xenoport inc (XNPT)

Name (Connections)Board RelationshipsTitle
Paul Berns 43 RelationshipsIndependent Director and Chairman of Compensation Committee
Dennis Fenton Ph.D. 232 RelationshipsDirector and Member of Compensation Committee
XNPT Compensation vs. Industry
500.0K
453.2K
Chief Executive Officer
380.3K
286.7K
Chief Financial Officer
439.2K
361.2K
Chief Operating Officer
Share price activity for XENOPORT INC (XNPT)
52 Week Price Performance
XNPT
Industry Average

Nominating Committee* - xenoport inc (XNPT)

Name (Connections)Board RelationshipsTitleKey Developments
John Freund M.D. 92 RelationshipsLead Director, Chairman of Nominating & Corporate Governance Committee and Member of Audit CommitteeXenoport, Inc. Announces Resignation of Gianna M. Bosko as Senior Vice President, Chief Legal Officer and Secretary, Effective as of February 28, 2015
02/19/15
Catherine Friedman 30 RelationshipsDirector, Member of Nominating & Corporate Governance Committee and Member of Audit CommitteeXenoport Appoints Richard Kim as Senior Vice President, Clinical Development and Medical Affairs, and Chief Medical Officer
02/8/14

Corporate Governance Committee* - xenoport inc (XNPT)

Name (Connections)Board RelationshipsTitle
John Freund M.D. 92 RelationshipsIndependent Director and Chairman of Compensation Committee
Catherine Friedman 30 RelationshipsDirector and Member of Compensation Committee
XNPT and Competitor
Insiders vs. External
Board
25%
75%
Xenoport, Inc.
29%
71%
Alkermes plc
8%
92%
Teva Pharmaceutical Industries Limited
11%
89%
Valeant Pharmaceuticals International, Inc.
20%
80%
Abeona Therapeutics Inc.
33%
67%
Skyepharma PLC
Insiders
External Board Members
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $7.10 USD -0.19

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $6.13 USD +0.18
Alkermes PLC $67.44 USD -1.95
Skyepharma PLC 282.00 GBp +3.00
Teva Pharmaceutical Industries Ltd $70.95 USD -0.46
Valeant Pharmaceuticals International Inc C$329.92 CAD -3.99
View Industry Companies
 

Industry Analysis

XNPT

Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.0x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.